Day One Biopharmaceuticals (DAWN) Short Interest Ratio & Short Volume $12.46 -0.18 (-1.42%) (As of 09:57 AM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Day One Biopharmaceuticals Short Interest DataDay One Biopharmaceuticals (DAWN) has a short interest of 19.49 million shares, representing 28.49% of the float (the number of shares available for trading by the public). This marks a 4.45% increase in short interest from the previous month. The short interest ratio (days to cover) is 17.9, indicating that it would take 17.9 days of the average trading volume of 953,958 shares to cover all short positions.Current Short Interest19,490,000 sharesPrevious Short Interest18,660,000 sharesChange Vs. Previous Month+4.45%Dollar Volume Sold Short$271.50 millionShort Interest Ratio17.9 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares100,846,000 sharesFloat Size68,400,000 sharesShort Percent of Float28.49%Today's Trading Volume47,534 sharesAverage Trading Volume953,958 sharesToday's Volume Vs. Average5% Short Selling Day One Biopharmaceuticals? Sign up to receive the latest short interest report for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartDAWN Short Interest Over TimeDAWN Days to Cover Over TimeDAWN Percentage of Float Shorted Over Time Ad Wall Street StarHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still simple, proof-of-concept systems. For its next act, AI is going to help save lives. Already better than humans at a number of medical tasks, AI is ramping up to completely revolutionize healthcare.Click here to learn more about the booming eHealth industry - and see which microcap will be at the Day One Biopharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/202419,490,000 shares $271.50 million +4.5%28.5%17.9 $13.93 11/15/202418,660,000 shares $248.36 million +3.6%27.3%17.6 $13.31 10/31/202418,020,000 shares $265.25 million +12.8%26.4%17.7 $14.72 10/15/202415,980,000 shares $236.98 million +2.0%26.9%16 $14.83 9/30/202415,670,000 shares $218.28 million +3.8%26.4%16 $13.93 9/15/202415,100,000 shares $213.36 million +7.2%25.5%15.4 $14.13 Get the Latest News and Ratings for DAWN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 8/31/202414,080,000 shares $194.87 million +3.8%23.8%14.4 $13.84 8/15/202413,570,000 shares $193.10 million +11.1%22.9%13.6 $14.23 7/31/202412,210,000 shares $174.73 million +6.0%20.1%12.5 $14.31 7/15/202411,520,000 shares $180.86 million +10.3%19.0%9.8 $15.70 6/30/202410,440,000 shares $143.86 million +1.5%17.2%8.9 $13.78 6/15/202410,290,000 shares $129.76 million -3.5%17.0%9 $12.61 5/31/202410,660,000 shares $141.46 million +0.6%17.6%9.5 $13.27 5/15/202410,600,000 shares $174.05 million -5.3%17.5%9.7 $16.42 4/30/202411,190,000 shares $191.35 million +25.2%18.5%10.7 $17.10 4/15/20248,940,000 shares $123.82 million -0.5%15.2%10.6 $13.85 3/31/20248,980,000 shares $148.35 million -6.6%15.2%14.5 $16.52 3/15/20249,610,000 shares $138.29 million -0.9%16.3%16.6 $14.39 2/29/20249,700,000 shares $162.28 million -0.2%16.5%17.3 $16.73 2/15/20249,720,000 shares $149.30 million +6.2%16.6%19.5 $15.36 1/31/20249,150,000 shares $137.71 million -15.3%15.5%17.4 $15.05 1/15/202410,800,000 shares $150.55 million +0.5%19.1%16.7 $13.94 12/31/202310,750,000 shares $156.95 million -2.3%19.0%15.1 $14.60 12/15/202311,000,000 shares $156.86 million +2.3%19.4%14.8 $14.26 11/30/202310,750,000 shares $124.49 million -0.7%19.0%13 $11.58 11/15/202310,830,000 shares $130.72 million -8.5%19.2%13.1 $12.07 10/31/202311,840,000 shares $140.07 million +4.3%21.0%14.1 $11.83 10/15/202311,350,000 shares $125.64 million -7.8%20.1%14.7 $11.07 9/30/202312,310,000 shares $151.04 million -0.5%21.3%16.7 $12.27 9/15/202312,370,000 shares $172.19 million +2.7%21.4%16 $13.92 8/31/202312,050,000 shares $162.55 million -0.2%20.4%13.2 $13.49 8/15/202312,070,000 shares $166.32 million -12.4%20.4%10.3 $13.78 7/31/202313,780,000 shares $182.45 million +1.0%30.1%11.5 $13.24 7/15/202313,640,000 shares $158.91 million -2.4%29.8%10.7 $11.65 6/30/202313,980,000 shares $166.92 million +3.5%30.6%11 $11.94 6/15/202313,510,000 shares $177.52 million +35.1%29.6%10.1 $13.14 5/31/202310,000,000 shares $133 million +7.2%21.5%8.8 $13.30 5/15/20239,330,000 shares $129.50 million +2.3%20.1%11.3 $13.88 4/30/20239,120,000 shares $113.09 million +16.0%20.0%11.7 $12.40 4/15/20237,860,000 shares $96.99 million +6.1%17.3%11.6 $12.34Could this be the hottest crypto discovery of all time? (Ad)I want to let you in on what may be the hottest crypto discovery of all time… One that has NOTHING to do with creating a crypto wallet or touching ANY risky coin for that matter. Instead, it’s a way that could let regular folks like you and me target 10X the possible results you’d expect from buying Bitcoin … in just a fraction of the time It sounds nuts… trust me I know that… But just as I would hate for you to jump into any risky crypto asset… That’s exactly how I would hate for you to miss out on what could be a safer and better way to benefit from the crypto bull run of 2024. Which is why I’m giving you an opportunity to get all the details of this iconic crypto discovery with you for the first time ever… completely free…If you want in, Just Click Here 3/31/20237,410,000 shares $99.07 million +11.3%16.3%10.7 $13.37 3/15/20236,660,000 shares $124.34 million +12.1%14.6%12.1 $18.67 2/28/20235,940,000 shares $109.41 million +4.4%13.0%10.7 $18.42 2/15/20235,690,000 shares $111.18 million +6.6%12.5%10.7 $19.54 1/31/20235,340,000 shares $116.25 million -4.5%11.6%10.1 $21.77 1/15/20235,590,000 shares $127.62 million +25.1%14.0%10.5 $22.83 12/30/20224,470,000 shares $96.19 million +3.5%11.2%8.4 $21.52 12/15/20224,320,000 shares $92.53 million -1.1%11.0%8.6 $21.42 11/30/20224,370,000 shares $92.78 million -4.2%11.1%7.3 $21.23 11/15/20224,560,000 shares $99.82 million -9.5%11.6%7.5 $21.89 10/31/20225,040,000 shares $106.55 million -7.9%12.7%7.7 $21.14 10/15/20225,470,000 shares $114.21 million -8.5%14.6%8.5 $20.88 9/30/20225,980,000 shares $119.78 million -3.1%17.0%9.5 $20.03 9/15/20226,170,000 shares $140.55 million -9.3%17.5%9 $22.78 8/31/20226,800,000 shares $159.73 million -6.7%21.3%4 $23.49 8/15/20227,290,000 shares $182.25 million -0.7%22.9%4.2 $25.00 7/31/20227,340,000 shares $125.73 million -6.0%24.3%4.4 $17.13 7/15/20227,810,000 shares $149.48 million +8.2%25.8%4.8 $19.14 6/30/20227,220,000 shares $129.24 million +0.6%23.2%4.5 $17.90 6/15/20227,180,000 shares $109.50 million +37.3%28.1%4.8 $15.25 5/31/20225,230,000 shares $32.53 million +9.2%23.8%17.8 $6.22 5/15/20224,790,000 shares $36.64 million +11.1%21.8%21.1 $7.65 4/30/20224,310,000 shares $36.72 million +6.4%19.8%20.2 $8.52 4/15/20224,050,000 shares $45.85 million +2.3%18.6%18.6 $11.32 3/31/20223,960,000 shares $39.28 million +0.5%N/A16.7 $9.92 3/15/20223,940,000 shares $41.29 million -1.3%18.1%16.1 $10.48 2/28/20223,990,000 shares $54.50 million +0.8%18.4%15.1 $13.66 2/15/20223,960,000 shares $54.61 million +4.8%18.2%14.6 $13.79 1/31/20223,780,000 shares $55.76 million +11.2%17.2%15.3 $14.75 1/15/20223,400,000 shares $47.91 million -1.2%N/A15.3 $14.09 12/31/20213,440,000 shares $57.96 million +30.3%14.8%18.7 $16.85 12/15/20212,640,000 shares $48.18 million +38.2%11.4%16 $18.25 11/30/20211,910,000 shares $35.09 million +6.1%8.8%16.2 $18.37 11/15/20211,800,000 shares $38.27 million -3.7%8.6%19.1 $21.26 10/29/20211,870,000 shares $45.70 million +1.6%8.9%17.7 $24.44 10/15/20211,840,000 shares $40.76 million +3.4%8.8%17.1 $22.15 9/30/20211,780,000 shares $42.24 million +6.6%8.5%16.2 $23.73 9/15/20211,670,000 shares $41.63 million +7.7%8.0%14.9 $24.93 8/31/20211,550,000 shares $43.14 million +22.1%7.8%19 $27.83 8/13/20211,270,000 shares $31.17 million No Change6.4%8.8 $24.54 DAWN Short Interest - Frequently Asked Questions What is Day One Biopharmaceuticals' current short interest? Short interest is the volume of Day One Biopharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of November 30th, investors have sold 19,490,000 shares of DAWN short. 28.49% of Day One Biopharmaceuticals' shares are currently sold short. Learn More on Day One Biopharmaceuticals' current short interest. What is a good short interest ratio for Day One Biopharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. DAWN shares currently have a short interest ratio of 18.0. Learn More on Day One Biopharmaceuticals's short interest ratio. Which institutional investors are shorting Day One Biopharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Day One Biopharmaceuticals: Barclays PLC, and Jane Street Group LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Day One Biopharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 28.49% of Day One Biopharmaceuticals' floating shares are currently sold short. Is Day One Biopharmaceuticals' short interest increasing or decreasing? Day One Biopharmaceuticals saw a increase in short interest in November. As of November 30th, there was short interest totaling 19,490,000 shares, an increase of 4.4% from the previous total of 18,660,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Day One Biopharmaceuticals' float size? Day One Biopharmaceuticals currently has issued a total of 100,846,000 shares. Some of Day One Biopharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Day One Biopharmaceuticals currently has a public float of 68,400,000 shares. How does Day One Biopharmaceuticals' short interest compare to its competitors? 28.49% of Day One Biopharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Day One Biopharmaceuticals: Crinetics Pharmaceuticals, Inc. (6.48%), Krystal Biotech, Inc. (12.69%), Arcellx, Inc. (12.85%), ADMA Biologics, Inc. (5.46%), Biohaven Ltd. (7.75%), Ultragenyx Pharmaceutical Inc. (3.66%), Apellis Pharmaceuticals, Inc. (17.53%), Immunovant, Inc. (20.39%), Avidity Biosciences, Inc. (12.52%), Scholar Rock Holding Co. (15.76%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short Day One Biopharmaceuticals stock? Short selling DAWN is an investing strategy that aims to generate trading profit from Day One Biopharmaceuticals as its price is falling. DAWN shares are trading up $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Day One Biopharmaceuticals? A short squeeze for Day One Biopharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of DAWN, which in turn drives the price of the stock up even further. How often is Day One Biopharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including DAWN, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies CRNX Short Interest KRYS Short Interest ACLX Short Interest ADMA Short Interest BHVN Short Interest RARE Short Interest APLS Short Interest IMVT Short Interest RNA Short Interest SRRK Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:DAWN) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
